Long-term foliow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-hodgkin's lymphoma

Joseph P. Colgan, Janet Andersen, Thomas Matthew Habermann, John D. Earle, Michael J. O'connell, Richard S. Neman, Risa B. Mann, John H. Glickk

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The Eastern Cooperative Oncology Group (ECOG) conducted a phase II trial in adult patients with lymphoblastic non-Hodgkin's lymphoma. Thirty-nine patients with no central nervous system (CNS) involvement were treated with an induction cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)/L-asparaginase regimen and CNS prophylaxis that included intrathecally administered methotrexate given 6 times and 24 Gy midplane cranial radiation in 12 fractions. Thirty-one patients (79% achieved a complete remission (CR). Of the 31 patients with CRs, 12 relapsed (39% CNS relapse occurred in three patients. All patients who entered a CR were treated with maintenance CHOP, cytosine arabinoside (Ara-C), and methotrexate and subsequently with Ara-C and methotrexate. Life-threatening leukopenia or thrombocytopenia was experienced in 69% of patients in the induction phase and in 70% in the maintenance phase. Nineteen of 39 patients (49% remain in CR with a follow-up to 9 years. Bone marrow involvement was associated with a significantly worse survival (P = 0.03).

Original languageEnglish (US)
Pages (from-to)291-296
Number of pages6
JournalLeukemia and Lymphoma
Volume15
Issue number3-4
DOIs
StatePublished - 1994

Fingerprint

Non-Hodgkin's Lymphoma
Central Nervous System
Cytarabine
Methotrexate
Therapeutics
Maintenance
Asparaginase
VAP-cyclo protocol
Leukopenia
Vincristine
Prednisone
Thrombocytopenia
Doxorubicin
Cyclophosphamide
Bone Marrow
Radiation
Recurrence
Survival

Keywords

  • CHOP/L-asparaginase regimen
  • CNS prophylaxis
  • Lymphoblastic
  • Non-Hodgkin's lymphoma
  • Phase II trial

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Long-term foliow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-hodgkin's lymphoma. / Colgan, Joseph P.; Andersen, Janet; Habermann, Thomas Matthew; Earle, John D.; O'connell, Michael J.; Neman, Richard S.; Mann, Risa B.; Glickk, John H.

In: Leukemia and Lymphoma, Vol. 15, No. 3-4, 1994, p. 291-296.

Research output: Contribution to journalArticle

Colgan, Joseph P. ; Andersen, Janet ; Habermann, Thomas Matthew ; Earle, John D. ; O'connell, Michael J. ; Neman, Richard S. ; Mann, Risa B. ; Glickk, John H. / Long-term foliow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-hodgkin's lymphoma. In: Leukemia and Lymphoma. 1994 ; Vol. 15, No. 3-4. pp. 291-296.
@article{82bacc20413e422899cba514de88b608,
title = "Long-term foliow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-hodgkin's lymphoma",
abstract = "The Eastern Cooperative Oncology Group (ECOG) conducted a phase II trial in adult patients with lymphoblastic non-Hodgkin's lymphoma. Thirty-nine patients with no central nervous system (CNS) involvement were treated with an induction cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)/L-asparaginase regimen and CNS prophylaxis that included intrathecally administered methotrexate given 6 times and 24 Gy midplane cranial radiation in 12 fractions. Thirty-one patients (79{\%} achieved a complete remission (CR). Of the 31 patients with CRs, 12 relapsed (39{\%} CNS relapse occurred in three patients. All patients who entered a CR were treated with maintenance CHOP, cytosine arabinoside (Ara-C), and methotrexate and subsequently with Ara-C and methotrexate. Life-threatening leukopenia or thrombocytopenia was experienced in 69{\%} of patients in the induction phase and in 70{\%} in the maintenance phase. Nineteen of 39 patients (49{\%} remain in CR with a follow-up to 9 years. Bone marrow involvement was associated with a significantly worse survival (P = 0.03).",
keywords = "CHOP/L-asparaginase regimen, CNS prophylaxis, Lymphoblastic, Non-Hodgkin's lymphoma, Phase II trial",
author = "Colgan, {Joseph P.} and Janet Andersen and Habermann, {Thomas Matthew} and Earle, {John D.} and O'connell, {Michael J.} and Neman, {Richard S.} and Mann, {Risa B.} and Glickk, {John H.}",
year = "1994",
doi = "10.3109/10428199409049726",
language = "English (US)",
volume = "15",
pages = "291--296",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "3-4",

}

TY - JOUR

T1 - Long-term foliow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-hodgkin's lymphoma

AU - Colgan, Joseph P.

AU - Andersen, Janet

AU - Habermann, Thomas Matthew

AU - Earle, John D.

AU - O'connell, Michael J.

AU - Neman, Richard S.

AU - Mann, Risa B.

AU - Glickk, John H.

PY - 1994

Y1 - 1994

N2 - The Eastern Cooperative Oncology Group (ECOG) conducted a phase II trial in adult patients with lymphoblastic non-Hodgkin's lymphoma. Thirty-nine patients with no central nervous system (CNS) involvement were treated with an induction cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)/L-asparaginase regimen and CNS prophylaxis that included intrathecally administered methotrexate given 6 times and 24 Gy midplane cranial radiation in 12 fractions. Thirty-one patients (79% achieved a complete remission (CR). Of the 31 patients with CRs, 12 relapsed (39% CNS relapse occurred in three patients. All patients who entered a CR were treated with maintenance CHOP, cytosine arabinoside (Ara-C), and methotrexate and subsequently with Ara-C and methotrexate. Life-threatening leukopenia or thrombocytopenia was experienced in 69% of patients in the induction phase and in 70% in the maintenance phase. Nineteen of 39 patients (49% remain in CR with a follow-up to 9 years. Bone marrow involvement was associated with a significantly worse survival (P = 0.03).

AB - The Eastern Cooperative Oncology Group (ECOG) conducted a phase II trial in adult patients with lymphoblastic non-Hodgkin's lymphoma. Thirty-nine patients with no central nervous system (CNS) involvement were treated with an induction cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)/L-asparaginase regimen and CNS prophylaxis that included intrathecally administered methotrexate given 6 times and 24 Gy midplane cranial radiation in 12 fractions. Thirty-one patients (79% achieved a complete remission (CR). Of the 31 patients with CRs, 12 relapsed (39% CNS relapse occurred in three patients. All patients who entered a CR were treated with maintenance CHOP, cytosine arabinoside (Ara-C), and methotrexate and subsequently with Ara-C and methotrexate. Life-threatening leukopenia or thrombocytopenia was experienced in 69% of patients in the induction phase and in 70% in the maintenance phase. Nineteen of 39 patients (49% remain in CR with a follow-up to 9 years. Bone marrow involvement was associated with a significantly worse survival (P = 0.03).

KW - CHOP/L-asparaginase regimen

KW - CNS prophylaxis

KW - Lymphoblastic

KW - Non-Hodgkin's lymphoma

KW - Phase II trial

UR - http://www.scopus.com/inward/record.url?scp=0028171062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028171062&partnerID=8YFLogxK

U2 - 10.3109/10428199409049726

DO - 10.3109/10428199409049726

M3 - Article

C2 - 7866277

AN - SCOPUS:0028171062

VL - 15

SP - 291

EP - 296

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 3-4

ER -